Breast Cancer breast cancer, chemotherapy, meal kit intervention, quality of life, metabolomics
Conditions
Interventions
Subjects will be randomly assigned in a 1:1 ratio to a group using the meal kit for the first 3 months (Group A) and a group using the meal kit for the last 3 months (Group B). Group A will use a meal
Mealkit
Sponsors
Fushimi Atsushi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diagnosed with breast cancer through pathological examination Diagnosed with clinical stages 0 to III through imaging Planned to start perioperative chemotherapy (including anthracycline and taxane) 20 years old or older Performance Status (PS) of 0 or 1 Written consent obtained for participation in this study
Exclusion criteria
Exclusion criteria: Cases with excessive food allergies Cases where written consent for this study was not obtained Cases with mental disorders deemed difficult to participate in this study Cases judged inappropriate as study subjects by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the "appetite loss" domain score of the EORTC QLQ-C30 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the total score of the EORTC QLQ-C30 Change in the domain scores of the EORTC QLQ-C30 Change in metabolite profiles by plasma metabolome analysis Change in weight, BMI, and body composition Change in nutritional status assessment by Subjective Global Assessment (SGA) Change in serum albumin, hemoglobin, zinc, and vitamin D levels Completion rate and relative dose intensity of chemotherapy Incidence rate of adverse events, incidence rate of Grade 3 or higher adverse events | — |
Contacts
Public ContactAtsushi Fushimi
The Jikei University School of Medicine
Outcome results
None listed